Mereo Biopharma
Mereo Biopharma has two late-stage assets, seeks non-dilutive financing for alvelestat Phase 3 trials, and reports cash runway through 2027.
NASDAQ
Mereo BioPharma Group plc
MREO
1 story
$49M Market cap · 2026-10-15
NASDAQ
MREO
1 story
$49M Market cap · 2026-10-15
Mereo Biopharma has two late-stage assets, seeks non-dilutive financing for alvelestat Phase 3 trials, and reports cash runway through 2027.